分红方面，安旭生物A股上市后累计派现8.95亿元。近三年，累计派现6.57亿元。 机构持仓方面，截止2025年6月30日，安旭生物十大流通股东中，广发价值核心混合A（010377）位居 第五大流通股东，持股301.47万股，持股数量较上期不变。招商景气优选股票A（009864）位居第八大 流通股东，持股60.00万股，相比上期减少1.00万股。博时凤凰领航混合A（013450）位居第九大流通股 东，持股52.89万股，为新进股东。 责任编辑：小浪快报 融券方面，安旭生物8月25日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00元； 融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，杭州安旭生物科技股份有限公司位于浙江省杭州市莫干山路1418-50号4幢5层，成立日期 2008年7月4日，上市日期2021年11月18日，公司主营业务涉及POCT试剂及仪器的研发、生产与销售。 主营业务收入构成为：快速诊断试剂100.00%。 截至6月30日，安旭生物股东户数6024.00，较上期增加1.50%；人均流通股21096股，较上期减少 1.48%。2025 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-027 杭州安旭生物科技股份有限公司 关于完成董事会换届选举暨聘任高级管理人员、 证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"） 于 2025 年 8 月 22 日召开 2025 年第一次临时股东大会，选举产生的第三届董事会成员，与公 司于 2025 年 8 月 6 日召开的职工代表大会选举的职工代表董事共同组成第三届董 事会。同日，公司召开第三届董事会第一次会议，审议通过了选举公司董事长、各 专门委员会委员、聘任第三届高级管理人员和证券事务代表等相关议案。现将具体 情况公告如下： 一、董事会换届选举情况 （一）董事选举情况 2025 年 8 月 6 日，公司召开职工代表大会选举董文坤先生为公司第三届董 事会职工代表董事。2025 年 8 月 22 日，公司召开 2025 年第一次临时股东大会， 审议通过了《关于董事会换届选举暨选举第三届董事会非独立董事的议案》《关 于董事会换 ...

本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688075 证券简称：安旭生物 公告编号：2025-025 杭州安旭生物科技股份有限公司 2025年第一次临时股东大会决议公告 （二） 股东大会召开的地点：浙江省杭州市莫干山路 1418-50 号 4 幢 5 楼大会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 46 | | --- | --- | | 普通股股东人数 | 46 | | 2、出席会议的股东所持有的表决权数量 | 81,577,525 | | 普通股股东所持有表决权数量 | 81,577,525 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 64.1924 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 64.1924 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会采用现场投票与网络投票相结合的方式对本 ...

证券代码：688075 证券简称：安旭生物 公告编号：2025-026 杭州安旭生物科技股份有限公司 第三届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 杭州安旭生物科技股份有限公司（以下简称"公司"或"安旭生物"）第三届董事 会第一次会议于 2025 年 8 月 22 日在公司会议室以现场方式召开，会议通知于 2025 年 8 月 22 日 2025 年第一次临时股东大会审议通过后即下发通知并送达各新一届董 事，经全体董事一致同意，豁免本次会议通知时间的要求。本次会议与会董事共同 推举凌世生先生主持，会议应到董事 7 人，实到董事 7 人，高级管理人员列席了会 议。本次会议的召集、召开符合《中华人民共和国公司法》等法律、法规、规章、 规范性文件和《公司章程》的有关规定，会议形成的决议合法、有效。 二、董事会会议审议情况 （一） 审议通过《关于选举公司第三届董事会董事长的议案》 同意选举凌世生先生为公司第三届董事会董事长，任期与本届董事会任期一致。 表决结果：同意 7 票 ...

法律意见书 上海市锦天城律师事务所 关于杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会的 地址： 上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 传真: 021-20511999 电话: 021-20511000 邮编: 200120 上海市锦天城律师事务所 致:杭州安旭生物科技股份有限公司 法律意见书 锦 天 城 律师事务 所 ALLBRIGHT LAW OFFICES 为出具本法律意见书,本所及本所律师依据《律师事务所从事证券法律业务 管理办法》和《律师事务所证券法律业务执业规则(试行)》等规定,严格履行 了法定职责,遵循了勤勉尽责和诚实信用原则,对本次股东大会所涉及的相关事 项进行了必要的核查和验证,核查了本所认为出具该法律意见书所需的相关文件、 资料,并参加了公司本次股东大会的全过程。本所保证本法律意见书所认定的事 实真实、准确、完整,所发表的结论性意见合法、准确,不存在虚假记载、误导 性陈述或者重大遗漏,并愿意承担相应法律责任。 关于杭州安旭生物科技股份有限公司 2025 年第一次临时股东大会的 法律意见书 上海市锦天城律师事务所 上海市锦天城律师事务所(以下简称" ...

Core Viewpoint - Anxu Bio (688075) reported a decline in revenue and net profit for the first half of 2025, indicating financial challenges and increased operational costs [1] Financial Performance - Total revenue for the first half of 2025 was 230 million yuan, a decrease of 7.42% year-on-year [1] - Net profit attributable to shareholders was 59.31 million yuan, down 48.57% compared to the previous year [1] - Gross margin was 39.11%, a decrease of 4.19% year-on-year, while net margin fell to 25.76%, down 44.64% [1] - Total expenses (selling, administrative, and financial) reached 60.04 million yuan, accounting for 26.13% of total revenue, an increase of 87.61% year-on-year [1] Cash Flow and Assets - Cash and cash equivalents decreased by 64.19% to 234 million yuan, attributed to increased investments in financial products [3] - Operating cash flow per share increased significantly by 1420.52% to 0.03 yuan, due to improved collections [11] Liabilities and Debt - Short-term borrowings decreased by 100% as the company repaid its debts [4] - Other current liabilities increased by 820.77% due to dividend distribution accruals [4] Operational Insights - Revenue decline of 7.42% was influenced by customers delaying orders due to increased tariffs from the U.S. [7] - Sales expenses rose by 19.83% as the company intensified market expansion efforts [9] - Management expenses increased by 3.1% due to normal operational fluctuations [10] Business Model and Market Position - The company has nine major technology platforms in the IVD industry, focusing on various diagnostic products including drug testing and infectious disease detection [12] - The company's return on invested capital (ROIC) was 2.98%, indicating weak capital returns, while historical data shows a median ROIC of 37.7% since its listing [11]

安旭生物8月20日股价报42.05元，较前一交易日下跌1.20%。公司最新发布的2025年半年报显示，上半 年实现营收2.30亿元，扣非净利润2358.62万元，同比增长24.89%。 公司主营业务为POCT试剂及仪器的研发、生产与销售。报告期内，公司通过国际国内"双轮驱动"战 略，在海外市场不确定性增加的背景下，保持了经营韧性。国内市场方面，公司新获多项医疗器械注册 证，包括呼吸道病毒抗原检测笔、胸痛三联笔等产品。同时通过"安旭科"品牌开拓电商平台C端市场， 形成B端与C端双轨发展模式。 风险提示：投资有风险，入市需谨慎。公司面临海外市场政策变化、汇率波动等风险因素。 来源：金融界 ...

Core Viewpoint - Hangzhou Anxu Biotechnology Co., Ltd. has demonstrated operational resilience amid challenges in the in vitro diagnostics (IVD) industry, including intensified centralized procurement and changes in the international trade environment, by actively adjusting its market strategies [1][3]. Financial Performance - In the first half of 2025, the company reported revenue of 230 million yuan and a net profit of 23.5862 million yuan after deducting non-recurring items [1]. Market Strategy - The company has adopted a "dual-wheel drive" strategy focusing on both international and domestic markets to address uncertainties in overseas markets, leading to a strong adaptability in overall operations despite performance fluctuations [1][3]. - In the domestic market, Anxu Biotechnology successfully obtained multiple medical device registration certificates, including for respiratory virus antigen detection and influenza virus antigen testing kits, targeting essential healthcare needs [1][2]. Business Expansion - The company has developed a dual-track model of "deepening B-end and breaking into C-end" by leveraging the "Anxu Ke" brand to expand into e-commerce, resulting in steady sales growth in home health management products [2]. - Anxu Biotechnology has established a "global network + localized service" system to strengthen its presence in traditional markets such as Europe, Oceania, Asia, and Africa, while also extending into emerging markets to mitigate single-market risks [2]. Diversification - The company is actively expanding into new fields while consolidating its traditional advantages in point-of-care testing (POCT). Its subsidiary, Taimengle, focuses on pet medical testing, developing over a hundred testing solutions for various infectious diseases and health monitoring [2]. - The company has launched the GluMate chronic disease management app, integrating existing POCT products into a comprehensive solution that includes hardware, software, and data services [2]. Industry Outlook - The global IVD market is projected to grow from $109.2 billion in 2024 to $135.1 billion by 2029, with strong growth expected in microfluidic technology and pet medical testing segments [3]. - Despite the overall pressure on the industry in the first half of 2025, the company has shown innovative vitality and resilience through its integrated supply chain, global layout, and diversified business strategies, laying a solid foundation for long-term healthy development [3].

Core Viewpoint - Anxu Bio maintains operational resilience amid challenges in the in vitro diagnostic (IVD) industry, reporting a slight revenue decline but significant profit growth in the first half of 2025 [1][2][3] Group 1: Financial Performance - The company's revenue for the first half of 2025 was 230 million yuan, a year-on-year decrease of 7.42% [1] - The net profit excluding non-recurring items reached 24 million yuan, reflecting a year-on-year increase of 24.89% [1] Group 2: Market Strategy - Anxu Bio has adopted a "dual-wheel drive" strategy focusing on both domestic and international markets to counteract external uncertainties, such as delayed customer orders due to tariffs [1][2] - The company has successfully registered multiple medical device certifications, enhancing its product offerings in critical areas like infectious disease prevention and cardiovascular emergencies [1] Group 3: Business Expansion - The launch of the "Anxu Ke" brand has allowed the company to penetrate the C-end market through e-commerce, establishing a dual-track model of deepening B-end and breaking into C-end markets [2] - Anxu Bio is expanding its presence in the pet medical testing sector through its subsidiary, targeting a market projected to reach 84.1 billion yuan in 2024, growing at 5.6% [2] Group 4: Future Outlook - The global IVD market is expected to grow from 109.2 billion USD in 2024 to 135.1 billion USD by 2029, with strong growth in microfluidic technology and pet medical testing [3] - Anxu Bio's strategy aligns with industry trends by focusing on a diversified product matrix and expanding both domestic and international markets, positioning itself for long-term growth [3]

Core Viewpoint - The company, Hangzhou Anxu Biotechnology Co., Ltd., has released its 2025 semi-annual report, which includes details on its financial status, operational results, and future development plans [1][7]. Group 1: Company Overview - The company is identified by the stock code 688075 and is referred to as Anxu Biotechnology [1]. - The report emphasizes the importance of reading the full semi-annual report for a comprehensive understanding of the company's performance and future plans [1]. Group 2: Financial Data - The total amount of funds raised through the public offering was RMB 1,200.30 million, with a net amount of RMB 1,055.85 million after deducting various fees [12]. - As of June 30, 2025, the balance of raised funds was RMB 27.59 million [13]. Group 3: Fund Management - The company has established a management system for the raised funds, ensuring that they are stored in designated special accounts and used according to regulations [14]. - The company has signed tripartite supervision agreements with banks to ensure proper management of the raised funds [15][16]. Group 4: Fund Usage - The company has completed several projects, reallocating surplus funds to new projects, including the "Technical R&D Headquarters Construction Project" with a planned investment of RMB 292.45 million [32][34]. - The company has not used idle raised funds to temporarily supplement working capital as of the reporting period [20]. Group 5: Compliance and Reporting - The company has complied with all relevant regulations regarding the management and use of raised funds, ensuring timely and accurate disclosures [35].